Anticoncepción en adolescentes

1. American Academy of Pediatrics, Committee on Adolescence. Policy statement: contraception for adolescents. Pediatrics.2014, In press
2. Eaton DK, Kann L, Kinchen S, et al; Centers for Disease Control and Prevention (CDC).Youth risk behavior surveillance - United States, 2011. MMWR Surveill Summ. 2012; 61(4):1–162
3. Kost K, Henshaw S, Carlin L. US Teenage Pregnancies, Births and Abortions: National and State Trends and Trends by Race and Ethnicity. New York, NY: Guttmacher Institute; 2010
4. Finer LB, Zolna MR. Unintended pregnancyin the United States: incidence and disparities, 2006. Contraception. 2011; 84(5):478–485
5. Santelli JS, Lindberg LD, Finer LB, Singh S.Explaining recent declines in adolescent pregnancy in the United States: the contribution of abstinence and improved contraceptive use. Am J Public Health. 2007; 97(1):150–156
6. Abma JC, Martinez GM, Copen CE. Teenagers in the United States: sexual activity, contraceptive use, and childbearing, national survey of family growth 2006-2008. Vital Health Stat 23. 2010; (30):1–47
7. Hagan JF, Shaw JS, Duncan PM. Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents. 3rd ed. Elk Grove Village, IL: American Academy of Pediatrics; 2008
8. Center for Adolescent Health and the Law. State Minor Consent Laws: A Summary. 3rd ed. Chapel Hill, NC: Center for Adolescent Health and the Law; 2010
9. Guttmacher Institute. An Overview of Minors’ Consent Law as of January 1, 2014. State Policies in Brief as of June 1, 2014. Available at: www.guttmacher.org/statecenter/spibs/spib_MACS.pdf. Accessed June 20, 2014
10. English A, Ford CA. The HIPAA privacy rule and adolescents: legal questions and clinical challenges. Perspect Sex Reprod Health. 2004; 36(2):80–86
11. Spooner SA; Council on Clinical Information Technology, American Academy of Pediatrics. Special requirements of electronic health record systems in pediatrics. Pediatrics. 2007; 119(3):631–637
12. Ford CA, Millstein SG, Halpern-Felsher BL, Irwin CE Jr. Influence of physician confidentiality
assurances on adolescents’ willingness to disclose information and seek future health care. A randomized controlled trial. JAMA. 1997; 278(12):1029–1034
13. Lehrer JA, Pantell R, Tebb K, Shafer MA. Forgone health care among U.S. adolescents: associations between risk characteristics and confidentiality concern. J Adolesc Health. 2007; 40(3):218–226
14. Lyren A, Kodish E, Lazebnik R, O’Riordan MA. Understanding confidentiality: perspectives of African American adolescents and their parents. J Adolesc Health. 2006; 39(2):261–265
15. Vo DX, Pate OL, Zhao H, Siu P, Ginsburg KR. Voices of Asian American youth: important
characteristics of clinicians and clinical sites. Pediatrics. 2007; 120(6). Available at: www.pediatrics.org/cgi/content/full/120/6/e1481
16. Blake DR, Kearney MH, Oakes JM, Druker SK, Bibace R. Improving participation in Chlamydia screening programs: perspectives of high-risk youth. Arch Pediatr Adolesc Med. 2003; 157(6):523–529
17. Committee On Adolescence. Office-based care for lesbian, gay, bisexual, transgender, and questioning youth. Pediatrics. 2013; 132(1):198–203
18. Klein JD, McNulty M, Flatau CN. Adolescents’ access to care: teenagers’ self reported use of services and perceived access to confidential care. Arch Pediatr Adolesc Med. 1998; 152(7):676–682
19. Reddy DM, Fleming R, Swain C. Effect of mandatory parental notification on adolescent
girls’ use of sexual health care services. JAMA. 2002; 288(6):710–714
20. Zabin LS, Stark HA, Emerson MR. Reasons for delay in contraceptive clinic utilization. Adolescent clinic and nonclinic populations compared. J Adolesc Health. 1991; 12(3):225–232
21. Guldi M. Fertility effects of abortion and birth control pill access for minors. Demography.
2008; 45(4):817–827
22. Zavodny M. Fertility and parental consent for minors to receive contraceptives. Am J Public Health. 2004; 94(8):1347–1351
23. Dempsey AF, Singer DD, Clark SJ, Davis MM. Adolescent preventive health care: what do parents want? J Pediatr. 2009; 155 (5):689.e1–694.e1
24. Jones RK, Purcell A, Singh S, Finer LB. Adolescents’ reports of parental knowledge of adolescents’ use of sexual health services and their reactions to mandated parental notification for prescription contraception. JAMA. 2005; 293(3):340–348
25. Ott MA, Rosenberger JG, McBride KR, Woodcox SG. How do adolescents view health? Implications for state health policy. J Adolesc Health. 2011; 48(4):398–403
26. Jones RK, Biddlecom AE. The more things change…: the relative importance of the Internet as a source of contraceptive information for teens. Sexual Research and Social Policy. 2011; 8(1):27 37
27. Brown JD, Wissow LS. Discussion of sensitive health topics with youth during primary care visits: relationship to youth perceptions of care. J Adolesc Health. 2009; 44(1):48–54
28. Centers for Disease Control and Prevention. A Guide to Taking a Sexual History. Atlanta, GA: Centers for Disease Control and Prevention; 2005
29. Ott MA, Pfeiffer EJ. “That’s nasty” to curiosity: early adolescent cognitions about sexual abstinence. J Adolesc Health. 2009; 44(6):575–581
30. Barnet B, Rapp T, DeVoe M, Mullins CD. Cost-effectiveness of a motivational intervention to reduce rapid repeated childbearing in high-risk adolescent mothers: a rebirth of economic and policy considerations. Arch Pediatr Adolesc Med. 2010; 164(4):370–376
31. Kamb ML, Fishbein M, Douglas JM Jr, et al; Project RESPECT Study Group. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. JAMA. 1998; 280(13):1161–1167
32. Rollnick S, Butler CC, Kinnersley P, Gregory J, Mash B. Motivational interviewing. BMJ. 2010; 340:c1900
33. Erickson SJ, Gerstle M, Feldstein SW. Brief interventions and motivational interviewing with children, adolescents, and their parents in pediatric health care settings: a review. Arch Pediatr Adolesc Med. 2005; 159(12):1173–1180
34. Blum RW. Healthy youth development as a model for youth health promotion. A review. J Adolesc Health. 1998; 22(5):368–375
35. Ott MA, Labbett RL, Gold MA. Counseling adolescents about abstinence in the office setting. J Pediatr Adolesc Gynecol. 2007; 20 (1):39–44
36. Ott MA, Millstein SG, Ofner S, Halpern- Felsher BL. Greater expectations: adolescents’
positive motivations for sex. Perspect Sex Reprod Health. 2006; 38(2):84–89
37. Ott MA, Pfeiffer EJ, Fortenberry JD. Perceptions of sexual abstinence among high-risk early and middle adolescents. J Adolesc Health. 2006; 39(2):192–198
38. Naar-King S, Suarez M. Motivational Interviewing with Adolescents and Young Adults. New York, NY: Guilford Press; 2010
39. Pinkerton SD. A relative risk-based, disease-specific definition of sexual abstinence failure rates. Health Educ Behav. 2001; 28(1):10–20
40. Brückner H, Bearman P. After the promise: the STD consequences of adolescent virginity pledges. J Adolesc Health. 2005; 36(4):271–278
41. Hatcher RA, Trussell J, Nelson AL, Cates W Jr, Kowal D, Policar MS. Contraceptive Technology. 20th rev ed. Valley Stream, NY: Ardent Media; 2011
42. Centers for Disease Control and Prevention. US selected practice recommendations for contraceptive use, 2013. MMWR Recomm Rep. 2013; 62(RR-5):1–60
43. Trussell J. Update on and correction to the cost-effectiveness of contraceptives in the United States. Contraception. 2012; 85(6):611
44. Graesslin O, Korver T. The contraceptive efficacy of Implanon: a review of clinical trials and marketing experience. Eur J Contracept Reprod Health Care. 2008; 13 (suppl 1):4–12
45. Levine JP, Sinofsky FE, Christ MF; Implanon US Study Group. Assessment of Implanon insertion and removal. Contraception. 2008; 78(5):409–417
46. Vidin E, Garbin O, Rodriguez B, Favre R, Bettahar-Lebugle K. Removal of etonogestrel contraceptive implants in the operating theater: report on 28 cases. Contraception. 2007; 76(1):35-39
47. Wechselberger G, Wolfram D, Pülzl P, Soelder E, Schoeller T. Nerve injury caused by removal
of an implantable hormonal contraceptive. Am J Obstet Gynecol. 2006; 195(1): 323–326
48. Guazzelli CA, de Queiroz FT, Barbieri M, Torloni MR, de Araujo FF. Etonogestrel implant in postpartum adolescents: bleeding pattern, efficacy and discontinuation rate. Contraception. 2010; 82(3):256–259
49. Lewis LN, Doherty DA, Hickey M, Skinner SR. Implanon as a contraceptive choice for teenage mothers: a comparison of contraceptive choices, acceptability and repeat pregnancy. Contraception. 2010; 81(5):421–426
50. Lakha F, Glasier AF. Continuation rates of Implanon in the UK: data from an observational
study in a clinical setting. Contraception. 2006; 74(4):287–289
51. Harvey C, Seib C, Lucke J. Continuation rates and reasons for removal among Implanon users accessing two family planning clinics in Queensland, Australia. Contraception. 2009; 80(6):527–532
52. Darney P, Patel A, Rosen K, Shapiro LS, Kaunitz AM. Safety and efficacy of a singlerod etonogestrel implant (Implanon): results from 11 international clinical trials. Fertil Steril. 2009; 91(5):1646–1653
53. Mansour D, Korver T, Marintcheva-Petrova M, Fraser IS. The effects of Implanon on menstrual
bleeding patterns. Eur J Contracept Reprod Health Care. 2008; 13(13 suppl 1):13–28
54. Mansour D, Bahamondes L, Critchley H, Darney P, Fraser IS. The management of unacceptable bleeding patterns in etonogestrel-releasing contraceptive implant users. Contraception. 2011; 83(3):202–210
55. Beerthuizen R, van Beek A, Massai R, Mäkäräinen L, Hout J, Bennink HC. Bone mineral density during long-term use of the progestagen contraceptive implant Implanon compared to a non-hormonal method of contraception. Hum Reprod.2000; 15(1):118–122
56. Bahamondes L, Monteiro-Dantas C, Espejo-Arce X, et al. A prospective study of the forearm
bone density of users of etonorgestreland levonorgestrel-releasing contraceptive implants. Hum Reprod. 2006; 21(2):466–470
57. Pongsatha S, Ekmahachai M, Suntornlimsiri N, Morakote N, Chaovisitsaree S. Bone mineral density in women using the subdermal contraceptive implant Implanon for at least 2 years. Int J Gynaecol Obstet. 2010; 109(3): 223–225
58. Centers for Disease Control and Prevention. US medical eligibility criteria for contraceptive use, 2010. MMWR Recomm Rep. 2010;59(RR-4):1–86
59. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 121: Long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol. 2011; 118(1):184–196
60. Skylab [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals; 2013. Available at: http://labeling.bayerhealthcare.com/html/products/pi/Skyla_PI.pdf. Accessed January 15, 2014
61. Marina [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals; 2013. Available at: http://labeling.bayerhealthcare.com/html/products/pi/Mirena_PI.pdf. Accessed January 15, 2014
62. Paraguarí [package insert]. Sellersville, PA: Tea Woman’s Health Inc/Tea Pharmaceuticals; 2011. Available at: http://paragard.com/Pdf/ParaGard-PI.pdf. June22, 2104
63. Long-term reversible contraception. Twelve years of experience with the TCu380A and TCu220C. Contraception. 1997; 56(6):341–352
64. Finer LB, Jerman J, Kavanaugh ML. Changes in use of long-acting contraceptive methods in the United States, 2007– 2009. Fertil Steril. 2012; 98(4):893–897
65. Hubacher D, Lara-Ricalde R, Taylor DJ, Guerra-Infante F, Guzmán-Rodríguez R. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med. 2001; 345(8):561–567
66. Hov GG, Skjeldestad FE, Hilstad T. Use of IUD and subsequent fertility—follow-up after participation in a randomized clinical trial. Contraception. 2007; 75(2):88–92
67. Penney G, Brechin S, de Souza A, et al; Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FFPRHC Guidance (January 2004). The copper intrauterine device as long-term contraception. J Fam Plann Reprod Health Care. 2004; 30(1):29–41, quiz 42
68. Mohllajee AP, Curtis KM, Peterson HB. Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review. Contraception. 2006; 73(2):145–153
69. Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet. 1992; 339 (8796):785–788
70. Grimes DA. Intrauterine device and uppergenital-tract infection. Lancet. 2000; 356 (9234):1013–1019
71. Hubacher D. Copper intrauterine device use by nulliparous women: review of side effects. Contraception. 2007; 75(suppl 6): S8–S11
72. Brockmeyer A, Kishen M, Webb A. Experience of IUD/IUS insertions and clinical performance in nulliparous women—a pilot study. Eur J Contracept Reprod Health Care. 2008; 13(3):248–254
73. Thonneau P, Almont T, de La Rochebrochard E, Maria B. Risk factors for IUD failure: results of a large multicentre case-control study. Hum Reprod. 2006; 21 (10):2612–2616
74. Suhonen S, Haukkamaa M, Jakobsson T, Rauramo I. Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study. Contraception. 2004; 69(5):407–412
75. Godfrey EM, Memmel LM, Neustadt A, et al. Intrauterine contraception for adolescents aged 14-18 years: a multicenter randomized pilot study of levonorgestrel releasing intrauterine system compared to the Copper T 380A. Contraception. 2010; 81(2):123–127
76. Paterson H, Ashton J, Harrison-Woolrych M. A nationwide cohort study of the use of the levonorgestrel intrauterine device in New Zealand adolescents. Contraception. 2009; 79(6):433–438
77. Pillai M, O’Brien K, Hill E. The levonorgestrel intrauterine system (Mirena) for the treatment of menstrual problems in adolescents with medical disorders, or
physical or learning disabilities. BJOG. 2010; 117(2):216–221
78. Toma A, Jamieson MA. Revisiting the intrauterine contraceptive device in adolescents.
J Pediatr Adolesc Gynecol. 2006; 19(4):291–296
79. Lara-Torre E, Spotswood L, Correia N, Weiss PM. Intrauterine contraception in adolescents and young women: a descriptive study of use, side effects, and compliance. J Pediatr Adolesc Gynecol. 2011; 24(1):39–41
80. Hillard PJ. Menstrual suppression with the levonorgestrel intrauterine system in girls with developmental delay. J Pediatr Adolesc Gynecol. 2012; 25(5):308–313
81. Hillman JB, Miller RJ, Inge TH. Menstrual concerns and intrauterine contraception among adolescent bariatric surgery patients. J Womens Health (Larchmt). 2011; 20(4):533–538
82. Kaunitz AM, Darney PD, Ross D, Wolter KD, Speroff L. Subcutaneous DMPA vs. intramuscular
DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density. Contraception. 2009; 80 (1):7–17
83. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG Committee Opinion No. 415: Depot medroxyprogesterone acetate and bone effects. Obstet Gynecol. 2008; 112(3):727–730
84. Kaunitz AM. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer. J Reprod Med. 1996; 41(suppl 5):419–427
85. Rodriguez MI, Kaunitz AM. An evidence based approach to postpartum use of depot medroxyprogesterone acetate in breastfeeding women. Contraception. 2009; 80(1):4–6
86. Herzog AG. Progesterone therapy in women with epilepsy: a 3-year follow-up. Neurology. 1999; 52(9):1917–1918
87. de Abood M, de Castillo Z, Guerrero F, Espino M, Austin KL. Effect of Depo-Provera or Microgynon on the painful crises of sickle cell anemia patients. Contraception. 1997; 56(5):313–316
88. Manchikanti A, Grimes DA, Lopez LM, Schulz KF. Steroid hormones for contraception in women with sickle cell disease. Cochrane Database Syst Rev. 2007; (2):CD006261
89. van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol. 2010; 30(11):2297–2300
90. Lestishock L, Pariseau C, Rooholamini S, Ammerman S. Anaphylaxis from depot medroxyprogesterone acetate in an adolescent girl. Obstet Gynecol. 2011; 118(2 pt 2): 443–445
91. Hubacher D, Lopez L, Steiner MJ, Dorflinger L. Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparisons. Contraception. 2009; 80(2):113–118
92. Arias RD, Jain JK, Brucker C, Ross D, Ray A. Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg. Contraception. 2006; 74(3): 234–238
93. Hubacher D, Goco N, Gonzalez B, Taylor D. Factors affecting continuation rates of DMPA. Contraception. 1999; 60(6):345–351
94. Canto De Cetina TE, Canto P, Ordoñez Luna M. Effect of counseling to improve compliance
in Mexican women receiving depot-medroxyprogesterone acetate. Contraception. 2001; 63(3):143–146
95. Jain J, Jakimiuk AJ, Bode FR, Ross D, Kaunitz AM. Contraceptive efficacy and safety of DMPA-SC. Contraception. 2004; 70 (4):269–275
96. Bonny AE, Ziegler J, Harvey R, Debanne SM, Secic M, Cromer BA. Weight gain in obese and no obese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method. Arch Pediatr Adolesc Med. 2006; 160(1):40–45
97. Espey E, Steinhart J, Ogburn T, Qualls C. Depo-provera associated with weight gain in Navajo women. Contraception. 2000; 62 (2):55–58
98. Risser WL, Gefter LR, Barratt MS, Risser JM. Weight change in adolescents who used hormonal contraception. J Adolesc Health. 1999; 24(6):433–436
99. Berenson AB, Rahman M. Changes in weight, total fat, percent body fat, and central-toperipheral fat ratio associated with injectable and oral contraceptive use. Am J Obstet Gynecol. 2009; 200(3):329.e1–329.e8
100. Mangan SA, Larsen PG, Hudson S. Overweight teens at increased risk for weight
gain while using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol. 2002; 15(2): 79–82
101. Lopez LM, Edelman A, Chen-Mok M, Trussell J, Helmerhorst FM. Progestin-only contraceptives: effects on weight. Cochrane Database Syst Rev. 2011; (4):CD008815
102. Bonny AE, Secic M, Cromer BA. A longitudinal comparison of body composition changes in adolescent girls receiving hormonal contraception. J Adolesc Health. 2009; 45(4):423–425
103. Bonny AE, Secic M, Cromer B. Early weight gain related to later weight gain in adolescents
on depot medroxyprogesterone acetate. Obstet Gynecol. 2011; 117(4):793–797
104. Le YC, Rahman M, Berenson AB. Early weight gain predicting later weight gain among depot medroxyprogesterone acetate users. Obstet Gynecol. 2009; 114(2 pt1):279–284
105. Cromer BA, Blair JM, Mahan JD, Zibners L, Naumovski Z. A prospective comparison of
bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr. 1996; 129 (5):671–676
106. Lara-Torre E, Edwards CP, Perlman S, Hertweck SP. Bone mineral density in adolescent females using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol. 2004; 17(1):17–21
107. Cromer BA, Stager M, Bonny A, et al. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J Adolesc Health. 2004; 35(6):434–441
108. Rome E, Ziegler J, Secic M, et al. Bone biochemical markers in adolescent girls using either depot medroxyprogesterone acetate or an oral contraceptive. J Pediatr Adolesc Gynecol. 2004; 17(6):373–377
109. DepoProvera 150 mg and Depo SubQ Provera 104 [package inserts]. Cambridge, MA: Pfizer; 2005
110. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med. 2005; 159(2):139–144
111. Harel Z, Johnson CC, Gold MA, et al. Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections. Contraception. 2010; 81(4):281–291
112. Berenson AB, Rahman M, Breitkopf CR, Bi LX. Effects of depot medroxyprogesterone acetate and 20-microgram oral contraceptives on bone mineral density. Obstet Gynecol. 2008; 112(4):788–799
113. Kaunitz AM, Grimes DA. Removing the black box warning for depot medroxyprogesterone
acetate. Contraception.2011; 84(3):212–213
114. Vestergaard P, Rejnmark L, Mosekilde L. The effects of depot medroxyprogesterone acetate and intrauterine device use on fracture risk in Danish women. Contraception. 2008; 78(6):459–464
115. Meier C, Brauchli YB, Jick SS, Kraenzlin ME, Meier CR. Use of depot medroxyprogesterone
acetate and fracture risk. J Clin Endocrinol Metab. 2010; 95(11):4909–4916
116. Institute of Medicine. Dietary reference intakes for calcium and vitamin D. Washington, DC: National Academies Press; 2010. Available at: www.iom.edu/Reports/2010/ Dietary-Reference-Intakes-for-calcium-andvitamin- D.aspx. Accessed January 15, 2014
117. Braverman PK, Breech L; Committee on Adolescence. American Academy of Pediatrics. Clinical report—gynecologic examination for adolescents in the pediatric office setting. Pediatrics. 2010; 126(3):583–590
118. Gallo MF, Grimes DA, Schulz KF, Helmerhorst FM. Combination estrogen-progestin contraceptives and body weight: systematic review of randomized controlled trials. Obstet Gynecol. 2004;103(2):359–373
119. Böttcher B, Radenbach K, Wildt L, Hinney B. Hormonal contraception and depression: a survey of the present state of knowledge. Arch Gynecol Obstet. 2012; 286
(1):231–236
120. Ott MA, Shew ML, Ofner S, Tu W, Fortenberry JD. The influence of hormonal contraception on mood and sexual interest among adolescents. Arch Sex Behav. 2008; 37(4):605–613
121. Dickey R. Managing Contraceptive Pill Patients. Fort Collins, CO: EMIS Inc Medical Publishers; 2010
122. Canobbio MM. Contraception for the adolescent and young adult with congenital heart disease. Nurs Clin North Am. 2004; 39(4):769–785
123. Trenor CC III, Chung RJ, Michelson AD, et al. Hormonal contraception and thrombotic risk: a multidisciplinary approach. Pediatrics. 2011; 127(2):347–357
124. Vandenbroucke JP, Rosing J, Bloemenkamp KW, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med. 2001; 344 (20):1527–1535
125. US Food and Drug Administration. Updated information about the risk of blood clots in women taking birth control pills containing drospirenone. Silver Spring, MD: US Food and Drug Administration; 2012. Available at: www.fda.gov/Drugs/DrugSafety/ ucm299305.htm. Accessed January 15, 2014
126. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of estrogen dose and progestogen type: results of the MEGA case-control study. BMJ. 2009; 339:b2921
127. Stein PD, Kayali F, Olson RE. Incidence of venous thromboembolism in infants and children: data from the National Hospital Discharge Survey. J Pediatr. 2004; 145(4):563–565
128. Walker ID. Venous and arterial thrombosis during pregnancy: epidemiology. Semin Vasc Med. 2003; 3(1):25–32
129. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ III. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30- year population-based study. Ann Intern Med. 2005; 143(10):697–706
130. Gaffield ME, Culwell KR, Lee CR. The use of hormonal contraception among women taking anticonvulsant therapy. Contraception. 2011; 83(1):16–29
131. Dickinson BD, Altman RD, Nielsen NH, Sterling ML; Council on Scientific Affairs, American Medical Association. Drug interactions between oral contraceptives and antibiotics. Obstet Gynecol. 2001 Nov; 98(5 Pt 1):853–60
132. Toh S, Mitchell AA, Anderka M, de Jong-van den Berg LT, Hernández-Díaz S; National Birth Defects Prevention Study. Antibiotics and oral contraceptive failure—a case crossover studies. Contraception. 2011; 83 (5):418–425
133. Sucato GS, Gold MA. Extended cycling of oral contraceptive pills for adolescents. J Pediatr Adolesc Gynecol. 2002; 15(5):325–327
134. Sucato GS, Gerschultz KL. Extended cycle hormonal contraception in adolescents. Curr Opin Obstet Gynecol. 2005; 17(5):461–465
135. Hamilton A, Marshal MP, Murray PJ. Autism spectrum disorders and menstruation. J Adolesc Health. 2011; 49(4):443–445
136. Schlaff WD, Lynch AM, Hughes HD, Cedars MI, Smith DL. Manipulation of the pill-free interval in oral contraceptive pill users: the effect on follicular suppression. Am J Obstet Gynecol. 2004; 190(4):943–951
137. Birtch RL, Olatunbosun OA, Pierson RA. Ovarian follicular dynamics during conventional vs. continuous oral contraceptive use. Contraception. 2006; 73(3):235–243
138. Baerwald AR, Olatunbosun OA, Pierson RA. Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use. Contraception. 2004; 70 (5):371–377
139. ACOG Committee on Practice Bulletins- Gynecology. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2006; 107(6):1453–1472
140. Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer. 2006; 95(3):385–389
141. Carey AS, Chiappetta L, Tremont K, Murray PJ, Gold MA. The contraceptive vaginal ring: female adolescents’ knowledge, attitudes and plans for use. Contraception. 2007; 76(6):444–450
142. Veres S, Miller L, Burington B. A comparison between the vaginal ring and oral contraceptives. Obstet Gynecol. 2004; 104 (3):555–563
143. Barnhart KT, Timbers K, Pretorius ES, Lin K, Shaunik A. In vivo assessment of NuvaRing placement. Contraception. 2005 72(3):196–199
144. Verhoeven CH, Dieben TO. The combined contraceptive vaginal ring, NuvaRing, and tampon co-usage. Contraception. 2004; 69 (3):197–199
145. Haring T, Mulders TM. The combined contraceptive ring NuvaRing and spermicide co-medication. Contraception. 2003; 67(4):271–272
146. Verhoeven CH, van den Heuvel MW, Mulders TM, Dieben TO. The contraceptive vaginal ring, NuvaRing, and antimycotic co-medication. Contraception. 2004; 69(2):129–132
147. Guida M, Di Spiezio Sardo A, Bramante S, et al. Effects of two types of hormonal contraception—oral versus intravaginal— on the sexual life of women and their partners. Hum Reprod. 2005; 20(4):1100–1106
148. Roumen FJ, Apter D, Mulders TM, Dieben TO. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod. 2001; 16(3):469–475 149. Dieben TO, Roumen FJ, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol. 2002; 100(3):585–593
150. Edwardson J, Jamshidi R. The contraceptive vaginal ring. Semin Reprod Med. 2010; 28(2):133–139
151. Massai R, Mäkäräinen L, Kuukankorpi A, Klipping C, Duijkers I, Dieben T. The combined contraceptive vaginal ring and bone mineral density in healthy pre-menopausal women. Hum Reprod. 2005; 20(10):2764–2768
152. Massaro M, Di Carlo C, Gargano V, Formisano C, Bifulco G, Nappi C. Effects of the contraceptive patch and the vaginal ring on bone metabolism and bone mineral density: a prospective, controlled, randomized study. Contraception. 2010; 81 (3):209–214
153. van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol
pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception. 2005; 72(3):168–174
154. Fleischer K, van Vliet HA, Rosendaal FR, Rosing J, Tchaikovski S, Helmerhorst FM. Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-over study. Thromb Res. 2009; 123(3):429–435
155. Jensen JT, Burke AE, Barnhart KT, Tillotson C, Messerle-Forbes M, Peters D. Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosis. Contraception. 2008; 78(6): 451–458
156. van Vliet HA, Rosendaal FR, Fleischer K, Rosing J, Helmerhorst FM. Effects of the contraceptive vaginal ring, the contraceptive transdermal patch and combined oral contraceptives on markers of hemostasis. Contraception. 2010; 81(1):88–89, author reply 89–90
157. Stewart FH, Brown BA, Raine TR, Weitz TA, Harper CC. Adolescent and young women’s experience with the vaginal ring and oral contraceptive pills. J Pediatr Adolesc Gynecol. 2007; 20(6):345–351
158. Gilliam ML, Neustadt A, Kozloski M, Mistretta S, Tilmon S, Godfrey E. Adherence and acceptability of the contraceptive ring compared with the pill among students: a randomized controlled trial. Obstet Gynecol. 2010; 115 (3):503–510
159. Timmer CJ, Mulders TM. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet. 2000; 39 (3):233–242
160. Miller L, Verhoeven CH, Hout J. Extended regimens of the contraceptive vaginal ring: a randomized trial. Obstet Gynecol. 2005; 106(3):473–482
161. Sulak PJ, Smith V, Coffee A, Witt I, Kuehl AL, Kuehl TJ. Frequency and management of breakthrough bleeding with continuous use of the transvaginal contraceptive ring: a randomized controlled trial. Obstet Gynecol. 2008; 112(3):563–571
162. Mosher WD, Jones J. Use of contraception in the United States: 1982-2008. Vital Health Stat 23. 2010 ;(29):1–44
163. Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction,
and stroke among transdermal contraceptive system users [published correction appears in Obstet Gynecol. 2008; 111(6):1449]. Obstet Gynecol. 2007; 109(2 pt 1):339–346
164. Dore DD, Norman H, Loughlin J, Seeger JD. Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users. Contraception. 2010; 81(5):408–413
165. Dore DD, Norman H, Seeger JD. Eligibility criteria in venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol. 2009; 114(1):175
166. Jick S, Kaye JA, Li L, Jick H. Further results on the risk of nonfatal venous thromboembolism
in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception. 2007; 76(1):4–7
167. Jick SS, Hagberg KW, Hernandez RK, Kaye JA. Postmarketing study of ORTHO EVRA and levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism. Contraception. 2010; 81(1):16–21
168. Jick SS, Hagberg KW, Kaye JA. ORTHO EVRA and venous thromboembolism: an update. Contraception. 2010; 81(5):452–453
169. Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel. Contraception. 2006; 73(6):566–570
170. Sidney S, Cheetham TC, Connell FA, et al. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users. Contraception. 2013; 87(1):93–100
171. Urdl W, Apter D, Alperstein A, et al; ORTHO EVRA/EVRA 003 Study Group. Contraceptive efficacy, compliance and beyond: factors related to satisfaction with once-weekly transdermal compared with oral contraception. Eur J Obstet Gynecol Reprod Biol. 2005; 121(2):202–210
172. Weisberg F, Bouchard C, Moreau M, et al; NRGEEP-CON-401 Study Group. Preference for and satisfaction of Canadian women with the transdermal contraceptive patch versus previous contraceptive method: an open-label, multicentre study. J Obstet Gynaecol Can. 2005; 27(4):350–359
173. Archer DF, Bigrigg A, Smallwood GH, Shangold GA, Creasy GW, Fisher AC. Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women. Fertil Steril. 2002; 77(2 suppl 2):S27–S31
174. Archer DF, Cullins V, Creasy GW, Fisher AC. The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy. Contraception. 2004; 69(3):189–195
175. Harel Z, Riggs S, Vaz R, Flanagan P, Dunn K, Harel D. Adolescents’ experience with the combined estrogen and progestin transdermal contraceptive method Ortho Evra. J Pediatr Adolesc Gynecol. 2005; 18(2):85–90
176. Rubinstein ML, Halpern-Felsher BL, Irwin CE Jr. An evaluation of the use of the transdermal contraceptive patch in adolescents. J Adolesc Health. 2004; 34 (5):395–401
177. Bakhru A, Stanwood N. Performance of contraceptive patch compared with oral contraceptive pill in a high-risk population. Obstet Gynecol. 2006; 108(2):378–386
178. LaGuardia KD. Performance of contraceptive patch compared with oral contraceptive pill in a high-risk population. Obstet Gynecol. 2006; 108(6):1553–1554
179. Sucato GS, Land SR, Murray PJ, Cecchini R, Gold MA. Adolescents’ experiences using the contraceptive patch versus pills. J Pediatr Adolesc Gynecol. 2011;24(4):197–203
180. Logsdon S, Richards J, Omar HA. Long-term evaluation of the use of the transdermal contraceptive patch in adolescents. Scientific World Journal. 2004; 4:512–516
181. Thurman AR, Hammond N, Brown HE, Roddy ME. Preventing repeat teen pregnancy: postpartum depot medroxyprogesterone acetate, oral contraceptive pills, or the patch? J Pediatr Adolesc Gynecol. 2007; 20(2):61–65
182. Lopez LM, Grimes DA, Gallo MF, Schulz KF. Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2010; (3):CD003552
183. Creinin MD, Meyn LA, Borgatta L, et al. Multicenter comparison of the contraceptive ring and patch: a randomized controlled trial. Obstet Gynecol. 2008; 111 (2 pt 1):267–277
184. Stricker T, Sennhauser FH. Allergic contact dermatitis due to transdermal contraception patch. J Pediatr. 2006; 148(6):845 185. Raine TR, Epstein LB, Harper CC, Brown BA, Boyer CB. Attitudes toward the vaginal ring and transdermal patch among adolescents and young women. J Adolesc Health. 2009; 45(3):262–267
186. Sucato GS, Bhatt SK, Murray PJ, Ott MA. Transdermal contraception as a model for adolescent use of new methods. J Adolesc Health. 2011; 49(4):357–362
187. Harel Z, Riggs S, Vaz R, Flanagan P, Harel D, Machan JT. Bone accretion in adolescents using the combined estrogen and progestin transdermal contraceptive method Ortho Evra: a pilot study. J Pediatr Adolesc Gynecol. 2010; 23(1):23–31
188. Martinez G, Copen CE, Abma JC. Teenagers in the United States: sexual activity, contraceptive use, and childbearing, 2006-2010 national survey of family growth.
Vital Health Stat 23. 2011; (31):1–35
189. Centers for Disease Control and Prevention. Male latex condoms and sexually transmitted diseases: condom fact sheet in brief. Atlanta, GA: Centers for Disease Control and Prevention. Available at: www.cdc.gov/condomeffectiveness/brief.html. Accessed January 15, 2014
190. Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ. 2004; 82(6):454–461
191. Gallo MF, Steiner MJ, Warner L, et al. self reported condom use is associated with reduced risk of Chlamydia, gonorrhea, and tricomoniasis. Sex Transom Dis. 2007; 34(10):829–833
192. Warner L, Makalu’s M, Newman D, et al. Condom effectiveness for prevention of C trachomatis infection. Sex Transom Infect. 2006; 82(3):265
193. Paz-Bailey G, Koumans EH, Sternberg M, et al. The effect of correct and consistent condom use on chlamydial and gonococcal infection among urban adolescents. Arch Pediatr Adolesc Med. 2005; 159(6):536–542
194. Niccolai LM, Rowhani-Rahbar A, Jenkins H, Green S, Dunne DW. Condom effectiveness for prevention of Chlamydia trachomatis infection. Sex Transm Infect. 2005; 81(4):323–325
195. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev. 2002; (1): CD003255
196. Martin ET, Krantz E, Gottlieb SL, et al. A pooled analysis of the effect of condoms in preventing HSV-2 acquisition. Arch Intern Med. 2009; 169(13):1233–1240
197. Stanaway JD, Wald A, Martin ET, Gottlieb SL, Magaret AS. Case-crossover analysis of condom use and herpes simplex virus type 2 acquisition. Sex Transm Dis. 2012; 39(5):388–393
198. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus
infection in young women. N Engl J Med. 2006; 354(25):2645–2654
199. Shew ML, Fortenberry JD, Tu W, et al. Association of condom use, sexual behaviors, and sexually transmitted infections with the duration of genital human papillomavirus infection among adolescent women. Arch Pediatr Adolesc Med. 2006; 160(2):151–156
200. Koss CA, Dunne EF, Warner L. A systematic review of epidemiologic studies assessing condom use and risk of syphilis. Sex Transm Dis. 2009; 36(7):401–405
201. American Academy of Pediatrics, Committee on Adolescence. Policy statement: condom use by adolescents. Pediatrics. 2013; 132(5):973–981
202. Matson PA, Adler NE, Millstein SG, Tschann JM, Ellen JM. Developmental changes in condom use among urban adolescent females: influence of partner context. J Adolesc Health. 2011; 48(4):386–390
203. Bearinger LH, Sieving RE, Duke NN, McMorris BJ, Stoddard S, Pettingell SL. Adolescent condom use consistency over time: global versus partner-specific measures. Nurs Res. 2011; 60(supple 3):S68–S78
204. Kenyon DB, Sieving RE, Jested SJ, Petting ell SL, Say CL. Individual, interpersonal, and relationship factors predicting hormonal and condom use consistency among adolescent girls. J Pediatric Health Care. 2010; 24 (4):241–249
205. Manning WD, Flanigan CM, Giordano PC, Longmore MA. Relationship dynamics and consistency of condom use among adolescents. Perspect Sex Reprod Health. 2009; 41(3):181–190
206. Ku L, Sonenstein FL, Pleck JH. The dynamics of young men’s condom use during and across relationships. Fam Plann Perspect. 1994; 26(6):246–251
207. Fortenberry JD, Tu W, Harezlak J, Katz BP, Orr DP. Condom use as a function of time in new and established adolescent sexual relationships. Am J Public Health. 2002; 92 (2):211–213
208. Fine P, Mathé H, Ginde S, Cullins V, Morfesis J, Gainer E. Ulipristal acetate taken 48-120 hours after intercourse for emergency contraception. Obstet Gynecol. 2010; 115(2pt 1):257–263
209. Glasier AF, Cameron ST, Fine PM, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet. 2010; 375(9714):555–562
210. Glasier A, Cameron ST, Blithe D, et al. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception. 2011; 84(4):363–367
211. Rockoff JD. FDA reviewing efficacy of Plan B contraception in women over 165 pounds. The Wall Street Journal. November 25, 2013. Available at: http://online. wsj.com/news/articles/SB10001424052702304011304579220533719517944. Accessed January 15, 2014
212. Grimes DA. Switching emergency contraception to over-the-counter status. N Engl J Med. 2002; 347(11):846–849
213. Committee on Adolescence. Emergency contraception. Pediatrics. 2012; 130(6):1174–1182
214. Leung VW, Soon JA, Levine M. Measuring and reporting of the treatment effect of hormonal emergency contraceptives. Pharmacotherapy. 2012; 32(3):210–221
215. Ellertson C, Ambardekar S, Hedley A, Coyaji K, Trussell J, Blanchard K. Emergency contraception: randomized comparison of advance provision and information only. Obstet Gynecol. 2001; 98 (4):570–575
216. Meyer JL, Gold MA, Haggerty CL. Advance provision of emergency contraception among adolescent and young adult women: a systematic review of literature. J Pediatr Adolesc Gynecol. 2011; 24(1):2–9
217. Bull SS, Posner SF, Ortiz C, Evans T. Knowledge of, attitudes toward, and stage of change for female and male condoms among Denver inner-city women. J Urban Health. 2003; 80(4):658–666
218. Wilkinson D, Tholandi M, Ramjee G, Rutherford GW. Nonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta-analysis of randomised controlled trials including more than 5000 women. Lancet Infect Dis. 2002; 2(10):613–617
219. Today Sponge—Vaginal Contraceptive Sponge [consumer information leaflet]. Berkeley, CA:
Myer Laboratories Inc; 2011. Available at: http://todaysponge.com/pdf/todaysponge-pi2. pdf. Accessed January 15, 2014
220. Vaughan B, Trussell J, Kost K, Singh S, Jones R. Discontinuation and resumption of contraceptive use: results from the 2002 National Survey of Family Growth. Contraception. 2008; 78(4):271–283
221. Grimes DA, Gallo MF, Grigorieva V, Nanda K, Schulz KF. Fertility awareness-based methods for contraception. Cochrane Database Syst Rev. 2004; (4):CD004860
222. Whittaker PG, Merkh RD, Henry-Moss D, Hock-Long L. Withdrawal attitudes and experiences: a qualitative perspective among young urban adults. Perspect Sex Reprod Health. 2010; 42(2):102–109
223. Bethell CD, Read D, Blumberg SJ, Newacheck PW. What is the prevalence of children with special health care needs? Toward an understanding of variations in findings and methods across three national surveys. Matern Child Health J. 2008; 12(1):1–14
224. McRee AL, Haydon AA, Halpern CT. Reproductive health of young adults with physical disabilities in the U.S. Prev Med. 2010;51(6):502–504
225. Surís JC, Resnick MD, Cassuto N, Blum RW. Sexual behavior of adolescents with chronic disease and disability. J Adolesc Health. 1996; 19(2):124–131
226. Murphy N. Sexuality in children and adolescents with disabilities. Dev Med Child Neurol. 2005; 47(9):640–644
227. Neufeld JA, Klingbeil F, Bryen DN, Silverman B, Thomas A. Adolescent sexuality and disability. Phys Med Rehabil Clin N Am. 2002; 13 (4):857–873
228. Worley G, Houlihan CM, Herman-Giddens ME, et al. Secondary sexual characteristics in children with cerebral palsy and moderate to severe motor impairment: a cross-sectional survey. Pediatrics. 2002; 110(5):897–902
229. Bauer J, Isojärvi JI, Herzog AG, et al. Reproductive dysfunction in women with epilepsy: recommendations for evaluation and management. J Neurol Neurosurg Psychiatry. 2002; 73(2):121–125
230. Dizon CD, Allen LM, Ornstein MP. Menstrual and contraceptive issues among young women with developmental delay: a retrospective review of cases at the Hospital for Sick Children, Toronto. J Pediatr Adolesc Gynecol. 2005; 18(3):157–162
231. American College of Obstetricians and Gynecologists Committee on Adolescent Health Care. ACOG Committee Opinion No.
448: Menstrual manipulation for adolescents with disabilities. Obstet Gynecol. 2009; 114(6):1428–1431
232. Quint EH. Menstrual issues in adolescents with physical and developmental disabilities. Ann N Y Acad Sci. 2008; 1135:230–236
233. Atkinson E, Bennett MJ, Dudley J, et al; Australian Society of Paediatric and Adolescent Gynaecology Working Party. Consensus statement: Menstrual and contraceptive management in women with an intellectual disability. Aust N Z J Obstet Gynaecol. 2003; 43(2):109–110
234. Akers AY, Lynch CP, Gold MA, et al. Exploring the relationship among weight, race, and sexual behaviors among girls. Pediatrics. 2009; 124(5). Available at: www. pediatrics.org/cgi/content/full/124/5/e913
235. Mond J, van den Berg P, Boutelle K, Hannan P, Neumark-Sztainer D. Obesity, body dissatisfaction, and emotional wellbeing in early and late adolescence: findings from the project EAT study. J Adolesc Health. 2011; 48(4):373–378
236. Audet MC, Moreau M, Koltun WD, et al; ORTHO EVRA/EVRA 004 Study Group. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA. 2001; 285(18): 2347–2354
237. Zieman M, Guillebaud J, Weisberg E, Shangold GA, Fisher AC, Creasy GW. Contraceptive
efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril. 2002; 77(2 suppl 2):S13–S18
238. Xu H, Wade JA, Peipert JF, Zhao Q, Madden T, Secura GM. Contraceptive failure rates
of etonogestrel subdermal implants in overweight and obese women. Obstet Gynecol. 2012; 120(1):21–26
239. Brunner Huber LR, Toth JL. Obesity and oral contraceptive failure: findings from the 2002 National Survey of Family Growth. Am J Epidemiol. 2007; 166(11):1306–1311
240. Hormonal contraceptives for contraception in overweight or obese women. Obstet Gynecol. 2010; 116(5):1206–1207
241. Gallo MF, Lopez LM, Grimes DA, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight. Cochrane Database Syst Rev. 2008; (4):CD003987
242. Lopez LM, Edelman A, Chen M, Otterness C, Trussell J, Helmerhorst FM. Progestin-only contraceptives: effects on weight. Cochrane Database Syst Rev. 2013; (7): CD008815
243. Vickery Z, Madden T, Zhao Q, Secura GM, Allsworth JE, Peipert JF. Weight change at 12 months in users of three progestin only contraceptive methods. Contraception. 2013; 88(4):503–508
244. American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 105: Bariatric surgery and pregnancy. Obstet Gynecol Clin North Am. 2009; 113(6): 1306–1311
245. Tepper NK, Curtis KM, Jamieson DJ, Marchbanks PA; Centers for Disease Control and Prevention (CDC). Update to CDC’s U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: revised recommendations for the use of hormonal contraception among women at high risk for
HIV infection or infected with HIV. MMWR Morb Mortal Wkly Rep. 2012; 61(24):449–452
246. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1- infected adults and adolescents. Washington, DC: Department of Health and Human Services; 2011. Updated February 2013. Available at: www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed January 15, 2014
247. Cupples SA. Cardiac transplantation in women. Crit Care Nurs Clin North Am. 1997; 9(4):521–533
248. Laifer SA, Darby MJ, Scantlebury VP, Harger JH, Caritis SN. Pregnancy and liver
transplantation. Obstet Gynecol. 1990; 76 (6):1083–1088
249. Shaben TR. Psychosocial issues in kidneytransplanted children and adolescents: literature review. ANNA J. 1993; 20(6):663– 668
250. Henning P, Tomlinson L, Rigden SP, Haycock GB, Chantler C. Long term outcome of treatment of end stage renal failure. Arch Dis Child. 1988; 63(1):35–40
251. Melzer SM, Leadbeater B, Reisman L, Jaffe LR, Lieberman KV. Characteristics of social networks in adolescents with end-stage renal disease treated with renal transplantation. J Adolesc Health Care. 1989; 10 (4):308–312
252. Morel P, Almond PS, Matas AJ, et al. Longterm quality of life after kidney transplantation in childhood. Transplantation. 1991; 52(1):47–53
253. Ghahramani N, Behzadi A, Gholami S, et al. Postrenal transplant improvement of sexual function. Transplant Proc. 1999; 31 (8):3144
254. O’Donnell D. Contraception in the female transplant recipient. Dial Transplant. 1986; 15(11):610–612
255. Kim JH, Chun CJ, Kang CM, Kwak JY. Kidney transplantation and menstrual changes. Transplant Proc. 1998; 30(7): 3057–3059
256. Britto MT, Rosenthal SL, Taylor J, Passo MH. Improving rheumatologists’ screening for alcohol use and sexual activity. Arch Pediatr Adolesc Med. 2000; 154(5):478–483
257. Riely CA. Contraception and pregnancy after liver transplantation. Liver Transpl. 2001; 7(11 suppl 1):S74–S76
258. Pietrzak B, Bobrowska K, Jabiry-Zieniewicz Z, et al. Oral and transdermal hormonal contraception in women after kidney transplantation. Transplant Proc. 2007; 39(9):2759–2762
259. Paternoster DM, Riboni F, Bertolino M, et al. The contraceptive vaginal ring in women with renal and liver transplantation: analysis of preliminary results. Transplant Proc. 2010; 42(4):1162–1165
260. Jabiry-Zieniewicz Z, Bobrowska K, Kaminski P, Wielgos M, Zieniewicz K, Krawczyk M. Lowdose hormonal contraception after liver transplantation. Transplant Proc. 2007; 39(5): 1530–1532
261. Deray G, le Hoang P, Cacoub P, Assogba U, Grippon P, Baumelou A. Oral contraceptive
interaction with cyclosporin. Lancet. 1987; 1(8525):158–159
262. Mastrobattista JM, Katz AR. Pregnancy after organ transplant. Obstet Gynecol Clin North Am. 2004; 31(2):415–428, vii
263. Estes CM, Westhoff C. Contraception for the transplant patient. Semin Perinatol. 2007; 31(6):372–377